Evidence map›Paper›PMID 22101116›Full record

ArticleEuropean urology2012

Evaluation of multiple risk-associated single nucleotide polymorphisms versus prostate-specific antigen at baseline to predict prostate cancer in unscreened men.

Robert J Klein, Christer Hallden, Amit Gupta, Caroline J Savage, Anders Dahlin, Anders Bjartell, Jonas Manjer, Peter T Scardino, David Ulmert, Peter Wallström and 2 more

Abstract readComparative Study
In one paragraph

Article in European urology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 2 pooled it
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 2 countries.

Robert J KleinProgram in Cancer Biology and Genetics, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA. kleinr@mskcc.org
Christer Hallden
Amit Gupta
Caroline J Savage
Anders Dahlin
Anders Bjartell
Jonas Manjer
Peter T Scardino
David Ulmert
Peter Wallström
Andrew J Vickers
Hans Lilja
Memorial Sloan Kettering Cancer Center · USLund University · SESkåne University Hospital · SE

Funding

SPORE In Prostate CancerP50CA092629 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Yu Chen, MICHAEL J MORRIS · 2001 to 2026
$63.0M
Long-term prediction of prostate cancer death from kallikreins measured in bloodR33CA127768 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI LILJA, HANS GÖSTA · 2010 to 2011
$692k
NCI NIH HHS P50 CA092629NCI NIH HHS P50-CA92629NCI NIH HHS R33 CA127768NCI NIH HHS R33 CA 127768-02
6 · The paper itself

Abstract

backgroundAlthough case-control studies have identified numerous single nucleotide polymorphisms (SNPs) associated with prostate cancer, the clinical role of these SNPs remains unclear.

objectiveEvaluate previously identified SNPs for association with prostate cancer and accuracy in predicting prostate cancer in a large prospective population-based cohort of unscreened men. DESIGN, SETTING, AND

participantsThis study used a nested case-control design based on the Malmö Diet and Cancer cohort with 943 men diagnosed with prostate cancer and 2829 matched controls. Blood samples were collected between 1991 and 1996, and follow-up lasted through 2005. MEASUREMENTS: We genotyped 50 SNPs, analyzed prostate-specific antigen (PSA) in blood from baseline, and tested for association with prostate cancer using the Cochran-Mantel-Haenszel test. We further developed a predictive model using SNPs nominally significant in univariate analysis and determined its accuracy to predict prostate cancer. RESULTS AND LIMITATIONS: Eighteen SNPs at 10 independent loci were associated with prostate cancer. Four independent SNPs at four independent loci remained significant after multiple test correction (p<0.001). Seven SNPs at five independent loci were associated with advanced prostate cancer defined as clinical stage≥T3 or evidence of metastasis at diagnosis. Four independent SNPs were associated with advanced or aggressive cancer defined as stage≥T3, metastasis, Gleason score≥8, or World Health Organization grade 3 at diagnosis. Prostate cancer risk prediction with SNPs alone was less accurate than with PSA at baseline (area under the curve of 0.57 vs 0.79), with no benefit from combining SNPs with PSA. This study is limited by our reliance on clinical diagnosis of prostate cancer; there are likely undiagnosed cases among our control group.

conclusionsOnly a few previously reported SNPs were associated with prostate cancer risk in the large prospective Diet and Cancer cohort in Malmö, Sweden. SNPs were less useful in predicting prostate cancer risk than PSA at baseline.

Indexed as

Polymorphism, Single NucleotideAgedBiomarkers, TumorCase-Control StudiesEarly Detection of CancerGenetic LociGenetic Predisposition to DiseaseHumansMaleMiddle AgedNeoplasm GradingNeoplasm StagingProspective StudiesProstate-Specific AntigenProstatic NeoplasmsRisk FactorsBiomarkers, TumorProstate-Specific Antigen

Identifiers

PMID22101116
PMCPMC3269546
OpenAlexW2044654750

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.